Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS: Diagnosis of non-Hodgkin's lymphoma (NHL) that has failed standard first-line chemotherapy Measurable disease NHL tissue Lym-1 reactive in vitro Normocellular bone marrow as evidenced by less than 25% of the bone marrow being NHL by bilateral bone marrow biopsy No bone marrow evidence of myelodysplastic syndrome HAMA titer negative PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life expectancy: 3 to 6 months Hematopoietic: Absolute neutrophil count at least 1,500/mm^3 Platelet count at least 130,000/mm^3 Hepatic: Bilirubin no greater than 1.5 mg/dL AST no greater than 84 U/L Renal: Creatinine less than 1.5 mg/dL OR Creatinine clearance at least 50 mL/min Cardiovascular: LVEF at least 50% Pulmonary: FEV1 at least 60% of predicted FVC at least 60% of predicted DLCO at least 50% Other: No other prior malignancy within the past 5 years except for nonmelanoma skin cancer HIV negative Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics At least 4 weeks since prior chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since prior external beam radiotherapy Surgery: Not specified